The Real-world Treatment Satisfaction by Gefapixiant in RCC
Recruiting
N/A
Interventional Study
Chronic Cough
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 63 (estimated)
- Sponsor
- Nagoya City University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Chronic cough has a high global prevalence and it is refractory to such treatments by approximately 20% of patients. Gafapixant is a P2X3 receptor antagonist that has demonstrated the reduction of cough in patients with refractory chronic cough(RCC). Taste disturbance is the most frequent adverse event by gefapixant (approximately 60-70%). Although gefapixant is well-tolerated even if taste distur…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Adult patients with RCC and UCC (8 weeks or more).
2. Cough is refractory to intensive specific treatments for causes of chronic cough.
3. Never smokers and ex-smokers with having smoking history of ≤20 pack-years.
Exclusion Criteria:
1. Patients with lung cancer, interstit…
Contacts